Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population.

Jupe ER, Dalessandri KM, Mulvihill JJ, Miike R, Knowlton NS, Pugh TW, Zhao LP, DeFreese DC, Manjeshwar S, Gramling BA, Wiencke JK, Benz CC.

BBA Clin. 2014 Nov 8;2:94-102. doi: 10.1016/j.bbacli.2014.11.001. eCollection 2014 Dec.

2.

Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study.

Dalessandri KM, Miike R, Wiencke JK, Farren G, Pugh TW, Manjeshwar S, DeFreese DC, Jupe ER.

J Am Coll Surg. 2012 Nov;215(5):652-7. doi: 10.1016/j.jamcollsurg.2012.06.413. Epub 2012 Aug 4.

PMID:
22867716
3.

Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.

Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, Defreese DC, Gramling BA, Evans I, White E.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1751-9. doi: 10.1158/1055-9965.EPI-08-0168.

4.

Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk.

Ralph DA, Zhao LP, Aston CE, Manjeshwar S, Pugh TW, DeFreese DC, Gramling BA, Shimasaki CD, Jupe ER.

Cancer. 2007 May 15;109(10):1940-8.

5.

Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens.

Prescott JL, Montie J, Pugh TW, McHugh T, Veltri RW.

Cancer. 2001 Jun 1;91(11):2127-35.

PMID:
11391594

Supplemental Content

Support Center